Stocks
Merck & Co Financial Statements (MRK) |
||||||||||
| Merck & Cosmart-lab.ru | % | 2020 | 2021 | 2022 | 2023 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 25.02.2021 | 25.02.2022 | 24.02.2023 | 31.12.2023 | 11.04.2024 | 06.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 41 518 | 48 704 | 59 283 | 59 871 | 60 115 | 63 218 | |||
| Operating Income, bln rub | 6 076 | 13 703 | 19 399 | 2 982 | 2 954 | 15 799 | ||||
| EBITDA, bln rub | ? | 10 180 | 17 899 | 21 315 | 6 854 | 6 907 | 17 655 | |||
| Net profit, bln rub | ? | 7 067 | 13 049 | 14 519 | 365.0 | 365.0 | 12 148 | |||
| OCF, bln rub | ? | 10 253 | 14 109 | 19 095 | 13 006 | 13 006 | 18 264 | |||
| CAPEX, bln rub | ? | 4 684 | 4 448 | 4 388 | 3 863 | 3 863 | 3 424 | |||
| FCF, bln rub | ? | 5 569 | 9 661 | 14 707 | 9 143 | 9 143 | 14 840 | |||
| Dividend payout, bln rub | 6 215 | 6 610 | 7 012 | 7 445 | 7 445 | 7 741 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 87.9% | 50.7% | 48.3% | 2 040% | 2 040% | 63.7% | ||||
| OPEX, bln rub | 22 352 | 21 879 | 23 590 | 40 912 | 43 989 | 32 995 | ||||
| Cost of production, bln rub | 13 618 | 13 626 | 17 411 | 15 977 | 16 126 | 14 994 | ||||
| R&D, bln rub | 13 397 | 12 245 | 13 548 | 30 530 | 30 531 | 22 343 | ||||
| Interest expenses, bln rub | 831.0 | 806.0 | 962.0 | 1 146 | 1 146 | 1 253 | ||||
| Assets, bln rub | 91 588 | 105 694 | 109 160 | 106 675 | 106 675 | 103 953 | ||||
| Net Assets, bln rub | ? | 25 317 | 38 184 | 45 991 | 37 581 | 37 581 | 44 502 | |||
| Debt, bln rub | 31 791 | 33 102 | 30 691 | 36 268 | 36 268 | 38 131 | ||||
| Cash, bln rub | 8 062 | 8 096 | 13 192 | 7 161 | 7 093 | 14 593 | ||||
| Net debt, bln rub | 23 729 | 25 006 | 17 499 | 29 107 | 29 175 | 23 538 | ||||
| Ordinary share price, rub | 78.0 | 76.6 | 111.0 | 109.0 | 109.0 | 102.9 | ||||
| Number of ordinary shares, mln | 2 530 | 2 530 | 2 532 | 2 537 | 2 607 | 2 532 | ||||
| Market cap, bln rub | 197 340 | 193 899 | 280 925 | 276 584 | 284 231 | 260 470 | ||||
| EV, bln rub | ? | 221 069 | 218 905 | 298 424 | 305 691 | 313 406 | 284 008 | |||
| Book value, bln rub | -9 525 | -6 013 | 4 518 | -1 627 | -1 627 | 5 795 | ||||
| EPS, rub | ? | 2.79 | 5.16 | 5.73 | 0.14 | 0.14 | 4.80 | |||
| FCF/share, rub | 2.20 | 3.82 | 5.81 | 3.60 | 3.51 | 5.86 | ||||
| BV/share, rub | -3.76 | -2.38 | 1.78 | -0.64 | -0.62 | 2.29 | ||||
| EBITDA margin, % | ? | 24.5% | 36.8% | 36.0% | 11.4% | 11.5% | 27.9% | |||
| Net margin, % | ? | 17.0% | 26.8% | 24.5% | 0.61% | 0.61% | 19.2% | |||
| FCF yield, % | ? | 2.82% | 4.98% | 5.24% | 3.31% | 3.22% | 5.70% | |||
| ROE, % | ? | 27.9% | 34.2% | 31.6% | 0.97% | 0.97% | 27.3% | |||
| ROA, % | ? | 7.72% | 12.3% | 13.3% | 0.34% | 0.34% | 11.7% | |||
| P/E | ? | 27.9 | 14.9 | 19.3 | 757.8 | 778.7 | 21.4 | |||
| P/FCF | 35.4 | 20.1 | 19.1 | 30.3 | 31.1 | 17.6 | ||||
| P/S | ? | 4.75 | 3.98 | 4.74 | 4.62 | 4.73 | 4.12 | |||
| P/BV | ? | -20.7 | -32.2 | 62.2 | -170.0 | -174.7 | 44.9 | |||
| EV/EBITDA | ? | 21.7 | 12.2 | 14.0 | 44.6 | 45.4 | 16.1 | |||
| Debt/EBITDA | 2.33 | 1.40 | 0.82 | 4.25 | 4.22 | 1.33 | ||||
| R&D/CAPEX, % | 286.0% | 275.3% | 308.8% | 790.3% | 790.3% | 652.5% | ||||
| CAPEX/Revenue, % | 11.3% | 9.13% | 7.40% | 6.45% | 6.43% | 5.42% | ||||
| Merck & Co shareholders | ||||||||||
